ESSA Pharma Inc.

ESSA Pharma Inc. (NASDAQ: EPIX) related to its sale to Xeno Acquisition Corp. Upon completion of the transaction, ESSA shareholders will receive a cash payment per share to be calculated based upon ESSA’s cash balance at closing minus transaction costs, liability and legal exposure review, and a $4 million transaction fee payable to Xeno. Additionally, ESSA shareholders are entitled to receive one non-transferable contingent value right per share entitling them to future payments based on (i) up to $150,000.00, less any remaining liabilities and expenses not deducted at closing; and (ii) up to $2.8 million, less legal and other expenses incurred after closing.

The investigation is focused on whether the process and price are fair. To receive more information regarding the investigation of ESSA Pharma Inc. please fill out the form below.

To start a Class Action lawsuit, please sign the ESSA Pharma Inc. Retainer Agreement

This confirms that you have retained Monteverde & Associates PC to pursue claims on your behalf and/or file a class action against the ESSA Pharma Inc. and/or its board of directors or officers with you as a named plaintiff and on a fully contingent basis with respect to our fees. Further, you purchased the shares prior to the announcement of the corporate action sought by the board of directors for ESSA Pharma Inc. and you did not buy said shares to commence any legal action. Furthermore, you must preserve all documents and communications related to ESSA Pharma Inc..

We agree to advance all expenses in the litigation, which means that you are not liable or responsible to pay any of the expenses of the action, whether attorneys’ fees or costs. Regardless of the result, we will never ask you to directly pay for any attorneys’ fees or costs. Should we obtain a favorable result, you authorize us to explore a release of all claims, and ask the court to award us compensation up to one-third of any monetary class fund plus expenses, or to negotiate a mootness fee with the company or defendants, but, we will never ask you to pay any of the fees or costs.

As the client you are entitled to direct the litigation in any way you deem proper, and may at any time order us to dismiss the case or opt-out. Should you choose to do so, we will never ask you to reimburse us directly for any legal fees or expenses. During the course of this litigation, you authorize us to employ, share work and/or fees with other attorneys or law firms to prosecute your case.  Further, the file compiled in the case constitutes the work product and property of this firm over which the firm has complete control with respect to its use and/or disclosure.

We look forward to representing you in this case.

Juan E. Monteverde, Esq.

AGREED: Sign Name

Signed pursuant to California Civil Code Section 1633. 1, et seq. – Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

Date of Signing: 08/29/2026